Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
주식 순위 #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
주가
$17.15
마지막 동기화: 2026-08-03
시가총액
$6.51M
변동 (1일)
9.80%
변동 (1년)
289.77%
국가
US
거래 Galera Therapeutics, Inc. (GRTX)

카테고리

Galera Therapeutics, Inc. (GRTX)의 주식 분할 이력
Galera Therapeutics, Inc. 주식 (심볼: GRTX)은 총 1회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Jul 13, 2026에 발생했습니다.
Jul 13, 2026 이전에 매수한 GRTX 주식 1주는 현재 0.005주의 GRTX 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
2026-07-13 1:200 x0.005 x0.005
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE